<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35664993</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2022.05.23.493121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2022.05.23.493121</ELocationID><Abstract><AbstractText Label="UNLABELLED">Infection by SARS-CoV-2 leads to diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse COVID-19 outcomes. Instead, we discovered that antibodies against specific chemokines are omnipresent after COVID-19, associated with favorable disease, and predictive of lack of long COVID symptoms at one year post infection. Anti-chemokine antibodies are present also in HIV-1 infection and autoimmune disorders, but they target different chemokines than those in COVID-19. Monoclonal antibodies derived from COVID- 19 convalescents that bind to the chemokine N-loop impair cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising anti-chemokine antibodies associated with favorable COVID-19 may be beneficial by modulating the inflammatory response and thus bear therapeutic potential.</AbstractText><AbstractText Label="ONE-SENTENCE SUMMARY" NlmCategory="UNASSIGNED">Naturally arising anti-chemokine antibodies associate with favorable COVID-19 and predict lack of long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muri</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchinato</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Institute of Bioinformatics; Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanbhag</LastName><ForeName>Akanksha A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matkovic</LastName><ForeName>Milos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biggiogero</LastName><ForeName>Maira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maida</LastName><ForeName>Pier Andrea</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritz</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toscano</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghovehoud</LastName><ForeName>Elaheh</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furlan</LastName><ForeName>Raffaello</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbic</LastName><ForeName>Franca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voza</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadai</LastName><ForeName>Guendalina De</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Emergency Medicine Residency School, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 - 20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervia</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurbuchen</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taeschler</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Lilly A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Lyme &amp; Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danelon-Sargenti</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piffaretti</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crivelli</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pode&#x161;vov&#xe1;</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedotti</LastName><ForeName>Mattia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarrossay</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgrignani</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhr</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Synlab Suisse; Bioggio, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernasconi</LastName><ForeName>Enos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regional Hospital Lugano, Ente Ospedaliero Cantonale; Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe0; della Svizzera italiana; Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Andri</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern; Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia; Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciurea</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Zurich University Hospital, University of Zurich; Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocchi</LastName><ForeName>Marco B L</ForeName><Initials>MBL</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, Biostatistics Unit, University of Urbino; Urbino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varani</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Infection &amp; Immunity, Henry Wellcome Building, Cardiff University School of Medicine; Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottazzi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Lyme &amp; Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lyme Research Program at the New York State Psychiatric Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyman</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Faculty of Science, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantovani</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzoni</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco; Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzetti-Pellanda</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uguccioni</LastName><ForeName>Mariagrazia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbiani</LastName><ForeName>Davide F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana; Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AI138938</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI151698</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI111825</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Nat Immunol. 2023 Apr;24(4):604-611. doi: 10.1038/s41590-023-01445-w</RefSource><PMID Version="1">36879067</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Competing interests:</b> The Institute for Research in Biomedicine has filed a provisional patent application in connection with this work on which JMu, VCe, ACa, MUg and DFR are inventors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35664993</ArticleId><ArticleId IdType="pmc">PMC9164443</ArticleId><ArticleId IdType="doi">10.1101/2022.05.23.493121</ArticleId><ArticleId IdType="pii">2022.05.23.493121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497&#x2013;506 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92&#x2013;98 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Initiative C.-H.G. Mapping the human genetic architecture of COVID-19. Nature 600, 472&#x2013;477 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054&#x2013;1062 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S. &amp; Merad M. Pathological sequelae of long-haul COVID. Nat Immunol 23, 194&#x2013;202 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med 27, 1607&#x2013;1613 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A. et al. Post-acute COVID-19 syndrome. Nat Med 27, 601&#x2013;615 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B. &amp; Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E. &amp; Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ 376, e068993 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F. &amp; Iwasaki A. The immunology and immunopathology of COVID-19. Science 375, 1122&#x2013;1127 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23, 210&#x2013;216 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C. et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun 13, 446 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D. &amp; VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol 12, 698169 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachelerie F. et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66, 1&#x2013;79 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880466</ArticleId><ArticleId IdType="pubmed">24218476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K. et al. Chemokines in homeostasis and diseases. Cell Mol Immunol 15, 324&#x2013;334 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052829</ArticleId><ArticleId IdType="pubmed">29375126</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181, 1036&#x2013;1045 e1039 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 26, 842&#x2013;844 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Paludan S.R. &amp; Mogensen T.H. Innate immunological pathways in COVID-19 pathogenesis. Sci Immunol 7, eabm5505 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34995097</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil B.A., Elemam N.M. &amp; Maghazachi A.A. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J 19, 976&#x2013;988 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859556</ArticleId><ArticleId IdType="pubmed">33558827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>COMBAT-Consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell 185, 916&#x2013;938 e958 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776501</ArticleId><ArticleId IdType="pubmed">35216673</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell 183, 1479&#x2013;1495 e1420 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevrier S. et al. A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Rep Med 2, 100166 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7817872</ArticleId><ArticleId IdType="pubmed">33521697</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M. &amp; Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20, 355&#x2013;362 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendeiro A.F. et al. The spatial landscape of lung pathology during COVID-19 progression. Nature 593, 564&#x2013;569 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204801</ArticleId><ArticleId IdType="pubmed">33780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch D. et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell 184, 6243&#x2013;6261 e6227 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin D.O. et al. Cytokine storm of a different flavour: The different cytokine signature of SARS-CoV-2, the cause of COVID-19, from the original SARS outbreak. J Glob Antimicrob Resist 24, 90&#x2013;92 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682938</ArticleId><ArticleId IdType="pubmed">33242672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A. et al. Long Covid: where we stand and challenges ahead. Cell Death Differ 29, 1891&#x2013;1900 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Angriman F. et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med 9, 655&#x2013;664 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078877</ArticleId><ArticleId IdType="pubmed">33930329</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot A.E. &amp; Uguccioni M. Modulation of Chemokine Responses: Synergy and Cooperativity. Front Immunol 7, 183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871875</ArticleId><ArticleId IdType="pubmed">27242790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisand K. et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207, 299&#x2013;308 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822605</ArticleId><ArticleId IdType="pubmed">20123959</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel A. et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180, 647&#x2013;654 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18097067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann B. et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 115, 2480&#x2013;2488 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1190367</ArticleId><ArticleId IdType="pubmed">16127458</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux J. et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev 21, 103012 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656211</ArticleId><ArticleId IdType="pubmed">34896650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 12, 5417 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 12 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci 13, 1077&#x2013;1086 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst M.G.P. et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med 13, eabh2624 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C. et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 611, 139&#x2013;147 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283&#x2013;288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump M.P. et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16, 6996&#x2013;7007 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170303</ArticleId><ArticleId IdType="pubmed">9384579</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani D.F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437&#x2013;442 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639&#x2013;644 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallais F. et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine 71, 103561 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390300</ArticleId><ArticleId IdType="pubmed">34455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Quintela A. et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 151, 42&#x2013;50 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276914</ArticleId><ArticleId IdType="pubmed">18005364</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881&#x2013;895 e820 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne S.K. &amp; Holland S.M. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis 10, 875&#x2013;885 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21109174</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D. &amp; Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 378, 2010&#x2013;2021 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeberg H. The major genetic risk factor for severe COVID-19 is associated with protection against HIV. Proc Natl Acad Sci U S A 119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892305</ArticleId><ArticleId IdType="pubmed">35193979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kousathanas A. et al. Whole genome sequencing reveals host factors underlying critical Covid-19. Nature (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259496</ArticleId><ArticleId IdType="pubmed">35255492</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe H.S. &amp; Leung B.P.L. Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus. Cells 9 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016754</ArticleId><ArticleId IdType="pubmed">31892200</ArticleId></ArticleIdList></Reference><Reference><Citation>Victora G.D. &amp; Nussenzweig M.C. Germinal centers. Annu Rev Immunol 30, 429&#x2013;457 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22224772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo R.C., Garzino-Demo A. &amp; DeVico A.L. HIV infection and pathogenesis: what about chemokines? J Clin Immunol 19, 293&#x2013;299 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10535605</ArticleId></ArticleIdList></Reference><Reference><Citation>Godessart N. &amp; Kunkel S.L. Chemokines in autoimmune disease. Curr Opin Immunol 13, 670&#x2013;675 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11677088</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson D., Watt J.A. &amp; Brissette C.A. Host transcriptome response to Borrelia burgdorferi sensu lato. Ticks Tick Borne Dis 12, 101638 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8127729</ArticleId><ArticleId IdType="pubmed">33360384</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger E.A., Murphy P.M. &amp; Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17, 657&#x2013;700 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10358771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouquet H. &amp; Nussenzweig M.C. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci 69, 1435&#x2013;1445 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11114792</ArticleId><ArticleId IdType="pubmed">22045557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercolini A.M. &amp; Miller S.D. The role of infections in autoimmune disease. Clin Exp Immunol 155, 1&#x2013;15 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665673</ArticleId><ArticleId IdType="pubmed">19076824</ArticleId></ArticleIdList></Reference><Reference><Citation>Suurmond J. &amp; Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest 125, 2194&#x2013;2202 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497746</ArticleId><ArticleId IdType="pubmed">25938780</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorda A. et al. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. Front Immunol 13, 817829 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8859444</ArticleId><ArticleId IdType="pubmed">35197981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kufareva I., Salanga C.L. &amp; Handel T.M. Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol Cell Biol 93, 372&#x2013;383 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406842</ArticleId><ArticleId IdType="pubmed">25708536</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403&#x2013;416 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383, 2603&#x2013;2615 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchinato V. et al. Impairment of CCR6+ and CXCR3+ Th Cell Migration in HIV-1 Infection Is Rescued by Modulating Actin Polymerization. J Immunol 198, 184&#x2013;195 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5164881</ArticleId><ArticleId IdType="pubmed">27895171</ArticleId></ArticleIdList></Reference><Reference><Citation>Stravalaci M. et al. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nat Immunol 23, 275&#x2013;286 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35102342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Rivero I. et al. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping. J Autoimmun 23, 63&#x2013;73 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15236754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrock E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 370 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857405</ArticleId><ArticleId IdType="pubmed">32994364</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark-Lewis I., Vo L., Owen P. &amp; Anderson J. Chemical synthesis, purification, and folding of C-X-C and C-C chemokines. Methods Enzymol 287, 233&#x2013;250 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330326</ArticleId></ArticleIdList></Reference><Reference><Citation>Moepps B. &amp; Thelen M. Monitoring Scavenging Activity of Chemokine Receptors. Methods Enzymol 570, 87&#x2013;118 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921943</ArticleId></ArticleIdList></Reference><Reference><Citation>De Gasparo R. et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature 593, 424&#x2013;428 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33767445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie P., Bardi G., Clark-Lewis I., Baggiolini M. &amp; Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 97, 1920&#x2013;1924 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11264152</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaslaver A., Feniger-Barish R. &amp; Ben-Baruch A. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2. J Immunol 166, 1272&#x2013;1284 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11145710</ArticleId></ArticleIdList></Reference><Reference><Citation>Loetscher M. et al. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr Biol 7, 652&#x2013;660 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9285716</ArticleId></ArticleIdList></Reference><Reference><Citation>Uguccioni M., D&#x2019;Apuzzo M., Loetscher M., Dewald B. &amp; Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 25, 64&#x2013;68 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7531149</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani D.F. et al. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell 169, 597&#x2013;609 e511 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492969</ArticleId><ArticleId IdType="pubmed">28475892</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiller T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329, 112&#x2013;124 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243222</ArticleId><ArticleId IdType="pubmed">17996249</ArticleId></ArticleIdList></Reference><Reference><Citation>von Boehmer L. et al. Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat Protoc 11, 1908&#x2013;1923 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27658009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J., Ma N., Madden T.L. &amp; Ostell J.M. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res 41, W34&#x2013;40 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692102</ArticleId><ArticleId IdType="pubmed">23671333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta N.T. et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics 31, 3356&#x2013;3358 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793929</ArticleId><ArticleId IdType="pubmed">26069265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 217 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372514</ArticleId><ArticleId IdType="pubmed">32692348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y. et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540, 458&#x2013;461 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5159191</ArticleId><ArticleId IdType="pubmed">27926736</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaik M.M. et al. Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature 565, 318&#x2013;323 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391877</ArticleId><ArticleId IdType="pubmed">30542158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasilko D.J. et al. Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20. Nat Commun 11, 3031 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295996</ArticleId><ArticleId IdType="pubmed">32541785</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46, W296&#x2013;W303 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaszczyk J. et al. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry 39, 14075&#x2013;14081 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11087354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>